AgingResearch.NewsJoin free

OKYO Pharma

CompanyUnited Kingdom

OKYO Pharma develops one asset, in phase 3 (urcosimod in neuropathic corneal pain). Mostly small molecule acting on inflammation and CMKLR1; based in the United Kingdom.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • urcosimod

    Agonist of ChemR23 (CMKLR1) resolving ocular neuropathic pain and inflammation

    Phase 3, Small molecule, Inflammation, CMKLR1, neuropathic corneal pain

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Similar companies6

Intelligence